Neuropathic Pain Clinical Trial
Official title:
A Multicenter, Randomized, Clinical Trial Comparing the Safety and Effectiveness of Axon Therapy and Conventional Medical Management (AT+CMM) for the Treatment of Painful Diabetic Neuropathy to Sham and Conventional Medical Management (Sham+CMM)
Verified date | August 2023 |
Source | NeuraLace Medical, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Compare Axon Therapy plus conventional medical management (CMM) to Sham plus CMM in reducing neuropathic pain in patients with painful diabetic neuropathy (PDM).
Status | Active, not recruiting |
Enrollment | 93 |
Est. completion date | November 2023 |
Est. primary completion date | August 23, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. Evidence of a personally signed and dated informed consent indicating that the subject has been informed of all pertinent aspects of the study. 2. Subject is willing and able to comply with scheduled visits, treatment plan, daily pain, and other study procedures subject is able and willing to complete twice daily electronic diary for up to 60 days. 3. Subject must be literate in English to fill out the study questionnaires. 4. Men or women of any race or ethnicity who are 18-85 years of age. 5. Subjects must not have a Body Mass Index >40. 6. Subject must have painful diabetic neuropathy (Type 2) present in the lower limbs for more than three months per medical history 7. Subject has a pain score =5 on VAS at Enrollment/Screening Visit. 8. Subject has completed at least one of the two daily pain diary entries on at least five days between the Enrollment/Screening Visit and Visit 1 with a mean pain score of =4 and <10 based on Daily VAS to be eligible for the study. 9. Subject is on a stable pain medication regimen or is not taking pain medications, as Exclusion Criteria: 1. Subjects with neuropathic pain due to post-herpetic neuropathy, HIV, trigeminal neuralgia; subjects whose post- traumatic neuropathic pain is categorized as central (e.g., spinal cord injury) rather than peripheral. 2. Subjects with any other chronic or recurrent pain syndrome rated greater than "mild" on a mild-moderate-severe scale, or which the investigator judges may interfere with the patients ability to report their pain accurately. 3. Any disorder that may be confused with PDN, such as tarsal tunnel syndrome, sciatica, bunions, ischemic claudication or arthritis of the feet or ankles. 4. Subject has a currently diagnosed progressive neurological disease such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, brain or spinal cord tumor, or severe/critical spinal stenosis (stenosis). 5. Subjects with skin conditions in the affected dermatome that in the judgment of the investigator could interfere with evaluation of the neuropathic pain condition. 6. Subjects with other pain that may confound assessment or self-evaluation of the peripheral neuropathic pain; subjects with significant somatic pain at the site of their trauma that may confound assessment or self-evaluation of their neuropathic pain. 7. Participation in any other clinical trial within the 30 days prior to screening and/or during participation in this study. 8. Any subject considered at risk of suicide or self-harm based on investigator judgment. 9. Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormality, or other factors that may increase the risk associated with study participation or investigational product administration or may interfere with compliance or the interpretation of study results and, in the judgment of the investigator would make the subject inappropriate to participate in the study. 10. Subjects with pending Worker's Compensation, Worker's Compensation, civil litigation, or disability claims. Subjects with fully resolved litigation and compensation claims can participate. 11. Subjects who have had a diagnosis of malignancy other than basal cell carcinoma, or carcinoma in situ of the cervix within the past five years, to include life expectancy less than 1 year due to advanced malignancy. 12. Subjects with implantable "electrical" medical devices such as a cardiac pacemaker, defibrillator, or insulin pump within four (4) inches or less of the site of pain to be treated by Axon Therapy. (Subject with an implantable device greater than four (4) inches from the site of pain to be treated should NOT be excluded). 13. Phantom limb pain or pain that feels like it is coming from a body part that is no longer there. 14. Subjects who have failed other neuromodulation implantable device for the same indication 15. Subjects with shrapnel or ferromagnetic objects 16. Subject is currently taking a morphine equivalent daily dose > 120 mg/day. 17. Subject is a woman of childbearing potential, not using adequate contraception or not willing to comply with contraception for the duration of the study. 18. Subjects with active drug or alcohol abuse within 1 year prior to screening. 19. Subjects with hemoglobin A1C of 9% or higher for 90 days prior to screening. |
Country | Name | City | State |
---|---|---|---|
United States | Centurion Spine and Pain Centers | Brunswick | Georgia |
United States | SC Pain and Spine Specialists, LLC | Murrells Inlet | South Carolina |
United States | Truwell Health | Saint Petersburg | Florida |
United States | Florida Pain Management Associates, P.A. | Sebastian | Florida |
United States | Florida Pain Management Associates, P.A. | Vero Beach | Florida |
United States | Centurion Spine and Pain Centers | Waycross | Georgia |
United States | Carolinas Pain Institute and Center for Clinical Research | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
NeuraLace Medical, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of the Proportion of Responders | The primary efficacy endpoint is a between groups comparison of pain change from baseline to 30 days. | 30 days | |
Primary | Comparison of therapy-related AEs between the 2 Study arms | The primary safety endpoint for this study is a comparison of therapy-related AEs through Day 30 between the 2 arms of the Study. | 30 days | |
Secondary | Visual Analog Scale (VAS) for Pain | Scores from daily diaries will be compared to baseline overall and by group (Axon therapy (AT) plus CMM and AT crossover (ATx) plus CMM) | 30- and 90-days post-treatment | |
Secondary | VAS for Numbness | Scores from daily diaries will be compared to baseline overall and by group (AT + CMM and ATx + CMM) | 30- and 90-days post-treatment | |
Secondary | Brief Pain Inventory (BPI) | Changes from baseline scores overall and by group (AT + CMM and ATx + CMM) | 30- and 90-days post-treatment | |
Secondary | Daily Sleep Interference Scale (DSIS) | Changes from baseline scores overall and by group (AT + CMM and ATx + CMM) | 30- and 90-days post-treatment | |
Secondary | EQ-5D-3L | Changes from baseline scores overall and by group (AT + CMM and ATx + CMM) | 30- and 90-days post-treatment | |
Secondary | Patient Global Impression of Change (PGIC) | Changes from baseline scores overall and by group (AT + CMM and ATx + CMM). In addition, the proportion of subjects with a minimal clinically important change from baseline will be compared between groups. | 30- and 90-days post-treatment | |
Secondary | Depression Anxiety Stress Scales (DASS) | Changes from baseline scores overall and by group (AT + CMM and ATx + CMM) | 30- and 90-days post-treatment | |
Secondary | Pain Disability Index (PDI) | Changes from baseline scores overall and by group (AT + CMM and ATx + CMM). In addition, the proportion of subjects with a minimal clinically important change from baseline will be compared between groups. | 30- and 90-days post-treatment | |
Secondary | Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) Questionnaire | Changes from baseline scores overall and by group (AT + CMM and ATx + CMM) | 30- and 90-days post-treatment | |
Secondary | In-clinic VAS Pain Scores | Changes from baseline scores overall and by group (AT + CMM and ATx + CMM) | 30- and 90-days post-treatment | |
Secondary | Increase from baseline pain medication within four weeks of the Day 90 visit (based on prescribed doses) | Changes from baseline scores overall and by group (AT + CMM and ATx + CMM) | 30- and 90-days post-treatment | |
Secondary | Proportion of subjects who discontinue treatment | Proportion of subjects who discontinue treatment will be compared between groups | 30- and 90-days post-treatment | |
Secondary | Neurological Exam - percentage of treatment arm with a change in neurological status | Percentage of treatment arm (including crossover subjects) with a change in neurological status as determined by neurological exam on Day 90 after start of active treatment. | 90 days post-treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04699734 -
Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Completed |
NCT05235191 -
Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies
|
Phase 3 | |
Completed |
NCT05845177 -
Persistent Pain After Hip Replacement
|
||
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT05949554 -
Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
|
||
Withdrawn |
NCT05052645 -
Ear Acupuncture for Neuropathic Pain
|
N/A | |
Completed |
NCT02866396 -
Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
|
||
Completed |
NCT02930551 -
Neuromas as the Cause of Pain
|
N/A | |
Completed |
NCT02824588 -
Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain
|
N/A | |
Active, not recruiting |
NCT02560545 -
Cannabinoids Effects on the Pain Modulation System
|
N/A | |
Enrolling by invitation |
NCT02485795 -
Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management
|
N/A | |
Not yet recruiting |
NCT02246517 -
The Effect of N2O on Chronic Neuropathic Pain Patients
|
Phase 0 | |
Completed |
NCT02099890 -
The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT01946555 -
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
|
N/A | |
Completed |
NCT01718821 -
Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients
|
N/A | |
Completed |
NCT01884662 -
Virtual Walking for Neuropathic Pain in Spinal Cord Injury
|
N/A | |
Completed |
NCT01669967 -
The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin
|
N/A | |
Completed |
NCT01201317 -
A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy
|
Phase 2 | |
Completed |
NCT01207596 -
Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain
|
Phase 4 |